Cartesian Therapeutics, Inc. (RNAC) stock
RNACNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.08−0.27 (-4.25%)
Close on Nov 16, 2026Market cap $183.95MP/E –Yield –
Cartesian Therapeutics cash
Cash and short-term investments held at the end of each period.
Cartesian Therapeutics's cash was $147.61M at Jun 30, 2026. For fiscal 2025 it was $125.14M, down 41.6% from the year before. Over ten years it grew 13.0% a year on average. The highest annual figure on record is $214.28M in fiscal 2024.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $125.14M | -41.6% |
| FY2024 | Dec 31, 2024 | $214.28M | +173.7% |
| FY2023 | Dec 31, 2023 | $78.29M | -42.5% |
| FY2022 | Dec 31, 2022 | $136.20M | +6.4% |
| FY2021 | Dec 31, 2021 | $128.06M | -8.6% |
| FY2020 | Dec 31, 2020 | $140.06M | +53.0% |
| FY2019 | Dec 31, 2019 | $91.55M | +143.0% |
| FY2018 | Dec 31, 2018 | $37.68M | -61.1% |
| FY2017 | Dec 31, 2017 | $96.97M | +14.7% |
| FY2016 | Dec 31, 2016 | $84.54M | +129.0% |
| FY2015 | Dec 31, 2015 | $36.91M | +122.5% |
| FY2014 | Dec 31, 2014 | $16.59M | +105.9% |
| FY2013 | Dec 31, 2013 | $8.06M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $147.61M | -7.9% |
| Q1 FY2026 | Mar 31, 2026 | $118.64M | -34.2% |
| Q4 FY2025 | Dec 31, 2025 | $125.14M | -41.6% |
| Q3 FY2025 | Sep 30, 2025 | $143.38M | -34.6% |
| Q2 FY2025 | Jun 30, 2025 | $160.32M | +83.8% |
| Q1 FY2025 | Mar 31, 2025 | $180.43M | +74.5% |
| Q4 FY2024 | Dec 31, 2024 | $214.28M | +173.7% |
| Q3 FY2024 | Sep 30, 2024 | $219.20M | +175.4% |
| Q2 FY2024 | Jun 30, 2024 | $87.23M | -22.1% |
| Q1 FY2024 | Mar 31, 2024 | $103.42M | -17.9% |
| Q4 FY2023 | Dec 31, 2023 | $78.29M | -42.5% |
| Q3 FY2023 | Sep 30, 2023 | $79.60M | -45.6% |
| Q2 FY2023 | Jun 30, 2023 | $112.03M | -21.1% |
| Q1 FY2023 | Mar 31, 2023 | $125.93M | +7.2% |
| Q4 FY2022 | Dec 31, 2022 | $136.20M | +6.4% |
| Q3 FY2022 | Sep 30, 2022 | $146.44M | +5.6% |
| Q2 FY2022 | Jun 30, 2022 | $142.06M | -5.4% |
| Q1 FY2022 | Mar 31, 2022 | $117.43M | -20.6% |
| Q4 FY2021 | Dec 31, 2021 | $128.06M | -8.6% |
| Q3 FY2021 | Sep 30, 2021 | $138.66M | -5.2% |
| Q2 FY2021 | Jun 30, 2021 | $150.14M | +151.4% |
| Q1 FY2021 | Mar 31, 2021 | $147.81M | +103.6% |
| Q4 FY2020 | Dec 31, 2020 | $140.06M | +53.0% |
| Q3 FY2020 | Sep 30, 2020 | $146.26M | +327.2% |
| Q2 FY2020 | Jun 30, 2020 | $59.73M | +43.3% |
| Q1 FY2020 | Mar 31, 2020 | $72.61M | +50.0% |
| Q4 FY2019 | Dec 31, 2019 | $91.55M | +143.0% |
| Q3 FY2019 | Sep 30, 2019 | $34.23M | -32.2% |
| Q2 FY2019 | Jun 30, 2019 | $41.68M | -37.1% |
| Q1 FY2019 | Mar 31, 2019 | $48.42M | -41.7% |
| Q4 FY2018 | Dec 31, 2018 | $37.68M | -61.1% |
| Q3 FY2018 | Sep 30, 2018 | $50.49M | -51.6% |
| Q2 FY2018 | Jun 30, 2018 | $66.23M | -41.2% |
| Q1 FY2018 | Mar 31, 2018 | $83.07M | +21.2% |
| Q4 FY2017 | Dec 31, 2017 | $96.97M | +14.7% |
| Q3 FY2017 | Sep 30, 2017 | $104.39M | +31.7% |
| Q2 FY2017 | Jun 30, 2017 | $112.66M | – |
| Q1 FY2017 | Mar 31, 2017 | $68.52M | – |
| Q4 FY2016 | Dec 31, 2016 | $84.54M | – |
| Q3 FY2016 | Sep 30, 2016 | $79.28M | – |
See a number that looks wrong?